Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Related Content:

OncLive TVColorectal CancerGastrointestinal CancerImmuno-Oncology
OncLive’s September Roundup of Key FDA Approvals in Oncology
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC
FDA Approves Cologuard Plus for Adults at Average Risk for CRC